Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 2, 2004, Pages

  Konner, Jason ^a   Dupont, Jakob ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antiagiogenesis; Antitumor effects; Bevacizumab; Decoy receptor; Heparin binding domains; Hypotension; Tyrosine kinase

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; PEGAPTANIB; PLACEBO; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY; VASCULOTROPIN TRAP;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE MODEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 7444261960     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.013     Document Type: Article

References (11)

1. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. 39th Annual Meeting of the American Society of Clinical Oncology 2003. Abstract #3646. Late-breaking abstract available at www.asco.org/hurwitzno_3646.
2. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of anti-angiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001; 98:4605-4610.
3. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393-11398.
4. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
5. Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273:20556-20567.
6. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002; 99:11399-11404.
7. Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6:373-378.
8. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5:3364-3368.
9. Breward CJ, Byrne HM, Lewis CE. A multiphase model describing vascular tumor growth. Bull Math Biol 2003; 65:609-640.
10. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003; 100:7785-7790.
11. Dupont J, Camastra D, Gordon MS, et al. Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. Proc Am Soc Clin Oncol 2003; 22:194 (Abstract #776).